Form 8-K - Current report:
SEC Accession No. 0001213900-25-034184
Filing Date
2025-04-22
Accepted
2025-04-22 16:05:14
Documents
15
Period of Report
2025-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239064-8k_nkgen.htm   iXBRL 8-K 31115
2 LOAN AGREEMENT AMENDMENT, DATED APRIL 14, 2025, BY AND BETWEEN NKGEN BIOTECH, IN ea023906401ex10-1_nkgen.htm EX-10.1 22966
  Complete submission text file 0001213900-25-034184.txt   278351

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nkgn-20250421.xsd EX-101.SCH 3881
4 XBRL DEFINITION FILE nkgn-20250421_def.xml EX-101.DEF 26778
5 XBRL LABEL FILE nkgn-20250421_lab.xml EX-101.LAB 37007
6 XBRL PRESENTATION FILE nkgn-20250421_pre.xml EX-101.PRE 25402
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239064-8k_nkgen_htm.xml XML 5591
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 25857710
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)